ZA201208535B - Formulations of quinones for the treatment of ophthalmic diseases - Google Patents
Formulations of quinones for the treatment of ophthalmic diseasesInfo
- Publication number
- ZA201208535B ZA201208535B ZA2012/08535A ZA201208535A ZA201208535B ZA 201208535 B ZA201208535 B ZA 201208535B ZA 2012/08535 A ZA2012/08535 A ZA 2012/08535A ZA 201208535 A ZA201208535 A ZA 201208535A ZA 201208535 B ZA201208535 B ZA 201208535B
- Authority
- ZA
- South Africa
- Prior art keywords
- quinones
- formulations
- treatment
- ophthalmic diseases
- ophthalmic
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000004053 quinones Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US39369310P | 2010-10-15 | 2010-10-15 | |
| PCT/US2011/033983 WO2011137126A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201208535B true ZA201208535B (en) | 2016-06-29 |
Family
ID=44861894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/08535A ZA201208535B (en) | 2010-04-27 | 2012-11-13 | Formulations of quinones for the treatment of ophthalmic diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (enExample) |
| EP (1) | EP2563352A4 (enExample) |
| JP (2) | JP5902673B2 (enExample) |
| CN (2) | CN105147651A (enExample) |
| AU (1) | AU2011245384C1 (enExample) |
| BR (1) | BR112012027543A8 (enExample) |
| CA (1) | CA2797581A1 (enExample) |
| EA (1) | EA201201465A1 (enExample) |
| MX (1) | MX337594B (enExample) |
| MY (1) | MY183449A (enExample) |
| SG (2) | SG10201801321XA (enExample) |
| WO (1) | WO2011137126A1 (enExample) |
| ZA (1) | ZA201208535B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| PL2220030T3 (pl) | 2007-11-06 | 2016-07-29 | Bioelectron Tech Corp | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| EP2237664A4 (en) | 2008-01-08 | 2013-05-22 | Edison Pharmaceuticals Inc | (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) * | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| NO2470168T3 (enExample) * | 2009-08-26 | 2018-06-30 | ||
| EA201201374A1 (ru) * | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| AU2011245384C1 (en) * | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| CA2842486C (en) | 2011-07-19 | 2022-09-06 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| CA2883879A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| HUE058877T2 (hu) | 2014-12-16 | 2022-09-28 | Ptc Therapeutics Inc | (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| HUE066196T2 (hu) | 2018-10-17 | 2024-07-28 | Ptc Therapeutics Inc | 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére |
| JP7705106B2 (ja) * | 2019-05-28 | 2025-07-09 | ナノ－ネオ リミテッド | 網膜症を治療するための組成物及び方法 |
| EP4366700A1 (en) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
| WO2025231245A1 (en) * | 2024-05-02 | 2025-11-06 | Stealth Biotherapeutics Inc. | Use of substituted 1,4 benzoquinones to treat alpha-synucleinopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035619B1 (ru) * | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| JP5122460B2 (ja) * | 2005-09-16 | 2013-01-16 | アラーガン、インコーポレイテッド | 治療薬の眼内輸送のための組成物および方法 |
| EP1986636B1 (en) * | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP2344142B1 (en) * | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| NO2470168T3 (enExample) * | 2009-08-26 | 2018-06-30 | ||
| EA201201374A1 (ru) * | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| AU2011245384C1 (en) * | 2010-04-27 | 2016-09-01 | Bioelectron Technology Corporation | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/en not_active Withdrawn
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 CA CA2797581A patent/CA2797581A1/en not_active Abandoned
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/en not_active Ceased
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6266674B2 (ja) | 2018-01-24 |
| AU2011245384C1 (en) | 2016-09-01 |
| EA201201465A1 (ru) | 2013-04-30 |
| SG10201801321XA (en) | 2018-04-27 |
| BR112012027543A2 (pt) | 2019-05-28 |
| CN105147651A (zh) | 2015-12-16 |
| EP2563352A1 (en) | 2013-03-06 |
| BR112012027543A8 (pt) | 2019-12-03 |
| JP2013525443A (ja) | 2013-06-20 |
| US20130109759A1 (en) | 2013-05-02 |
| JP2016106144A (ja) | 2016-06-16 |
| AU2011245384B2 (en) | 2016-02-18 |
| CA2797581A1 (en) | 2011-11-03 |
| CN102985083A (zh) | 2013-03-20 |
| WO2011137126A1 (en) | 2011-11-03 |
| US20170354618A1 (en) | 2017-12-14 |
| MX337594B (es) | 2016-03-11 |
| JP5902673B2 (ja) | 2016-04-13 |
| MX2012012518A (es) | 2012-12-17 |
| MY183449A (en) | 2021-02-18 |
| AU2011245384A1 (en) | 2012-12-06 |
| EP2563352A4 (en) | 2013-11-13 |
| SG185046A1 (en) | 2012-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201801321XA (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| LT2925757T (lt) | Junginiai ir kompozicijos, skirti parazitinių ligų gydymui | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| ZA201301601B (en) | Treatment of diseases | |
| BRPI1013377A2 (pt) | formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas | |
| IL275350B (en) | Treatment of neoplastic diseases | |
| GB2479213B (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| IL225668A0 (en) | The compositions for the treatment of disorders in the upper respiratory tract | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| PT2605769T (pt) | Derivados benziquinona como modeladores da função mitocondrial | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| GB201114289D0 (en) | Flurbiprofen and related compounds for the treatment of skin diseases | |
| PL2531124T3 (pl) | Urządzenia do leczenia zmian skórnych | |
| HK1182942A (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| EP2670421A2 (en) | Use of icam-1 for prevention or treatment of neurological diseases | |
| HK1168027A (en) | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases | |
| GB0901727D0 (en) | The treatment of ophthalmic diseases | |
| HK1182092A (en) | Arylosulfonamides for the treatment of cns diseases | |
| AU2011903764A0 (en) | Treatment of bone diseases | |
| IL232294A0 (en) | Preparations for the treatment of diabetes | |
| HK1188955A (en) | Methods for treating diseases of the retina | |
| HK1185284A (en) | Compounds for the treatment/prevention of ocular inflammatory diseases |